Without RCT, FDA May Consider Approval Of A Cross-Sex Hormone For Gender-Affirming Care
The FDA may consider approval of the cross-sex hormone estradiol for gender incongruence in adults and minors based on an observational study and not an RCT with placebo.
The FDA may consider approval of the cross-sex hormone estradiol for gender incongruence in adults and minors based on an observational study and not an RCT with placebo.
What's Your Reaction?
